Poster
T-DXd
ASCO 2026 | May 29 - June 2, 2026
Gastric Cancer
Additional health-related quality of life analysis from DESTINY-Gastric04, a randomized phase 3 study of trastuzumab deruxtecan vs ramucirumab + paclitaxel in patients with human epidermal growth factor receptor 2-positive unresectable/metastatic gastric cancer/gastroesophageal junction adenocarcinoma
Kohei Shitara
Poster
T-DXd
ASCO GI 2026 | January 8-10, 2026
Gastric Cancer
An open-label, randomized, multicenter, phase 3 study of trastuzumab deruxtecan (T-DXd) + chemotherapy ± pembrolizumab versus chemotherapy + trastuzumab ± pembrolizumab in first-line metastatic HER2+ gastric or gastroesophageal junction cancer: DESTINY-Gastric05
Kohei Shitara
Poster
T-DXd
ASCO GI 2026 | January 8-10, 2026
Gastric Cancer
Exploratory analysis of HER2 status based on central and local testing results from the DESTINY-Gastric04 study
Kohei Shitara
Poster
T-DXd
ASCO 2026 | May 29 - June 2, 2026
Gastric Cancer
First-line trastuzumab deruxtecan (T-DXd)–based regimens in advanced HER2‑expressing gastric cancer, gastroesophageal junction adenocarcinoma, gastroesophageal junction adenocarcinoma, or esophageal adenocarcinoma: Safety results from DESTINY-Gastric03 part 2 arms D and F, and Part 4
Yelena Y. Janjigian
Poster
T-DXd
ESMO Asia 2025 | December 5-7, 2025
Gastric Cancer
First-line trastuzumab deruxtecan 5.4 mg/kg and fluoropyrimidine with pembrolizumab in advanced HER2+ gastric cancer, gastroesophageal junction adenocarcinoma, or esophageal adenocarcinoma: Updated results from DESTINY-Gastric 03 part 2F
Yelena Y. Janjigian
Poster
T-DXd
AACR 2026 | April 17-22, 2026
Gastric Cancer
First-line trastuzumab deruxtecan regimens in advanced HER2-positive gastric cancer, gastroesophageal junction adenocarcinoma, or esophageal adenocarcinoma: Exploratory analysis of baseline HER2-related biomarkers
in DESTINY-Gastric03 part 2
Yelena Y. Janjigian
Poster
T-DXd
AACR 2026 | April 17-22, 2026
Gastric Cancer
First-line trastuzumab deruxtecan with rilvegostomig and fluoropyrimidine in HER2-positive gastric cancer, gastroesophageal junction adenocarcinoma, or esophageal adenocarcinoma: DESTINY-Gastric03 part 4 arm A results
Yelena Y. Janjigian
Poster
T-DXd
ASCO GI 2026 | January 8-10, 2026
Gastric Cancer
First-line trastuzumab deruxtecan with volrustomig and fluoropyrimidine in patients with HER2-low gastric cancer, gastroesophageal junction adenocarcinoma, or esophageal adenocarcinoma: DESTINY-Gastric03 part 5
Yelena Y. Janjigian
Poster
T-DXd
ASCO GI 2026 | January 8-10, 2026
Gastric Cancer
GEMINI-PeriOp Gastric: A phase 2 study of novel agent-based combinations as perioperative therapy for previously untreated, locally advanced resectable gastric, gastroesophageal junction, or esophageal adenocarcinoma
Ziyu Li
Oral
HER3-DXd
JSMO 2026 | March 26-28, 2026
Gastric Cancer
HERTHENA-PanTumor01: Expansion of a global phase 2 trial of HER3-DXd in patients with advanced/metastatic solid tumors
Izuma Nakayama